drug
abemaciclib
Marketedupdated 5mo agoby Eli Lilly and Co
Approvedannual revenue · 2024–2024peak $5.2B
community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying abemaciclib
- phase2Study of AVZO-021 in Patients With Advanced Solid Tumors
- phase1A Study of Abemaciclib (LY2835219) in Healthy Participants
- phase3A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- phase2Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
- phase2ALPINE: Maintenance Letrozole/Abemaciclib
- phase3BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- phase2Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
- phase3A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 28, 2031
~5.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Sep 28, 2031compositionUS 78552115.0y
- Sep 28, 2031compositionUS 78552115.0y
- Sep 28, 2031compositionUS 78552115.0y
- Sep 28, 2031compositionUS 78552115.0y
News(7)
- An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slideAlkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.biopharma_dive · 9d ago
- AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger marketSERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a setting that could have meant a $2.9 billion opportunity for the drug.biospace · 17d ago
- AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancerThe approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked forward to an upcoming late-stage readout that could lead to a “significant…biospace · 23d ago
- FDA Grants Accelerated Approval to a New Breast Cancer TreatmentThe U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting ne…fda_press · 27d ago
- RallyBio tries again for reverse merger, this time with AvenzoIt's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.biopharma_dive · 4mo ago
- #ASCO26: Lilly's plenaries; Incyte's frontline data in lymphomaTwo plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, show…endpoints · 4mo ago
- Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast CancerKelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.onclive · 4mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that